MedImmune Expands Scientific and Engineering ...(tion on a global level. Before joining A...),Health

Date:12/20/2007

tion on a global level. Before joining Amgen, Mr. Skibo served in engineering management positions focused on pharmaceuticals and bioscience at Skanska, Inc; Foster Wheeler Corp.; Life Sciences International, Inc.; A.D. Skibo & Associates, Inc.; and Genentech, Inc. Mr. Skibo holds a master of science degree in chemical engineering with a specialty in biomedical engineering and a bachelor of science degree in organic chemistry, both from Massachusetts Institute of Technology.

Management Promotion

As vice president, infectious disease research, Dr. Suzich is responsible for overseeing MedImmune's research in the development of antibodies and antibody-like molecules for the prophylaxis and treatment of infectious disease. Since joining MedImmune in 1988 in the role of scientist, she has held several positions of increasing responsibility, most recently as senior director, infectious disease research. During her tenure with the company she has been involved in many key development programs, including Synagis(R) (palivizumab) and the virus-like particle technology that is the basis of the new human papillomavirus (HPV) vaccines used to prevent cervical cancer. Dr. Suzich holds a doctorate in biochemistry from Purdue University and graduated magna cum laude with a bachelor of science degree in biology from Susquehanna University.

New Cambridge Site Leadership Team

MedImmune also announced today that following the integration of CAT into MedImmune, several personnel were appointed to the new Cambridge site leadership team under the guidance of John Stageman, Ph.D., vice president and interim site head.

Dr. Stageman has nearly 30 years of experience in R&D management throughout AZ and its predecessor companies, having pioneered large-scale biotechnology process development and scale-up at the start of his career. He entered the pharmaceutical business in 1993 rising through a number of senior roles in both drug discovery and development pr
'/>"/>

SOURCE MedImmune Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
4. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
5. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
6. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
7. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
8. Rohm and Haas Expands in India
9. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
10. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
11. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors